Mariner LLC Trims Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Mariner LLC lessened its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 26.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,511 shares of the medical equipment provider’s stock after selling 915 shares during the quarter. Mariner LLC’s holdings in Lantheus were worth $225,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of LNTH. Synovus Financial Corp boosted its position in Lantheus by 13.4% during the fourth quarter. Synovus Financial Corp now owns 25,639 shares of the medical equipment provider’s stock worth $2,294,000 after purchasing an additional 3,038 shares in the last quarter. Granite Investment Partners LLC boosted its position in shares of Lantheus by 3.2% during the 4th quarter. Granite Investment Partners LLC now owns 51,149 shares of the medical equipment provider’s stock valued at $4,576,000 after acquiring an additional 1,579 shares during the last quarter. Townsquare Capital LLC acquired a new position in Lantheus in the 4th quarter valued at about $1,108,000. Capital Fund Management S.A. grew its position in Lantheus by 180.5% in the fourth quarter. Capital Fund Management S.A. now owns 99,573 shares of the medical equipment provider’s stock worth $8,908,000 after acquiring an additional 64,078 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in shares of Lantheus during the 4th quarter worth $36,183,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Trading Down 2.9 %

Shares of LNTH opened at $104.84 on Wednesday. The company’s 50 day simple moving average is $100.46 and its 200-day simple moving average is $94.89. Lantheus Holdings, Inc. has a 12-month low of $74.28 and a 12-month high of $126.89. The firm has a market cap of $7.18 billion, a PE ratio of 17.44 and a beta of 0.23.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company had revenue of $391.11 million for the quarter, compared to analysts’ expectations of $376.61 million. As a group, equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Activity

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the sale, the director now directly owns 440,399 shares in the company, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the company’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares in the company, valued at $11,445,207.20. The trade was a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 63,109 shares of company stock valued at $6,016,046 over the last quarter. Corporate insiders own 1.50% of the company’s stock.

Analysts Set New Price Targets

LNTH has been the subject of a number of research analyst reports. Truist Financial increased their price objective on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. B. Riley lowered their price objective on Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research report on Friday, March 21st. Finally, JMP Securities reissued a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $134.33.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.